Sweden HIV Therapeutics Market Analysis Report [2022-30]

Sweden HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Sweden HIV therapeutics market will reach a value of $xx Mn from $49.54 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Recipharm AB, Oasmia Pharmaceutical AB, and Medivir AB. The market is driven by government policies, funding, and organizations’ initiatives for the management of HIV infections in the country. The HIV therapeutics market in Sweden is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10SEPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Sweden AUTHOR: Dr. Vishwa Modhia

Buy Now

Sweden HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Sweden HIV therapeutics market will reach a value of $xx Mn from $49.54 Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Sweden is a nation in northern Europe that borders the Baltic Sea, the Gulf of Bothnia, Kattegat, and Skagerrak. Sweden is ranked 157th in the world with an age-adjusted death rate of 0.1 per 100,000 people. The adult prevalence of HIV/AIDS in Sweden was 11,000 cases in 2020. Sweden has a relatively low prevalence of HIV compared to other countries.

However, the number of new infections has remained relatively stable over the past decade, with most new cases being attributed to high-risk behaviors such as unprotected sexual intercourse and injection drug use. Sweden spent 11.4% of its GDP on healthcare in 2019. The responsibility for health and medical care in Sweden is shared by the central government, the regions, and the municipalities. Sweden is divided into 290 municipalities and 21 regions.

sweden HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers

Early HIV diagnosis and treatment are highly valued in Sweden because they slow the spread of the disease and stop it from infecting others. In Sweden, efforts have been made to lessen stigma and discrimination toward those who are HIV-positive, which might persuade more people to get tested and receive treatment. This can drive the market for HIV therapeutics in Sweden.

Market Restraints

Although there is widespread access to ART, there are still barriers to other preventive measures like pre-exposure prophylaxis (PrEP) and condoms, especially for underserved communities. HIV prevention and treatment programs may receive insufficient funding, which may affect the accessibility and availability of these services.

Competitive Landscape

Key Players

Medivir AB (SWE)
Oasmia Pharmaceutical AB (SWE)
Recipharm AB (SWE)
BioArctic AB (SWE)
Pfizer
AstraZeneca
Novartis
GlaxoSmithKline

Recent Notable Update

July 2022: The Swedish government announced in July 2022 that it would boost its three-year, $290 Mn financial commitment to the Global Fund to Fight AIDS, Tuberculosis, and Malaria. With Sweden's assistance, the fund will be able to save 20 Mn lives and reduce mortality from diseases like HIV and AIDS, tuberculosis, and malaria by two-thirds.

Healthcare Regulations and Reimbursement Policies

The Swedish Medical Products Agency (MPA) and the European Medicines Agency (EMA) are two of the government organizations in charge of regulating HIV therapeutics in Sweden. The national regulatory body for medical products in Sweden is called the Swedish Medical Products Agency (MPA).

The Swedish national healthcare insurance system, which provides access to HIV therapeutics, covers a wide range of medical procedures and services, including HIV medications. The Swedish National Health Insurance, which is funded by taxes and other sources of income, typically pays for the cost of these medications. Regardless of their financial situation, patients with HIV/AIDS typically have access to the most recent and efficient treatments for the disease. This is because the Swedish government is firmly committed to giving all of its citizen's access to universal healthcare, including HIV therapeutics.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.